Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD.

ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome, which progresses from simple fat accumulation (steatosis) to nonalcoholic steatohepatitis (NASH), fibrosis, and eventually liver cancer. Stearoyl-CoA desaturase 1 (SCD1), a key lipogenic enzyme, plays a significant role in the progression of NAFLD by promoting the accumulation of fat in the liver. This study investigated the drug-nutraceutical combination of Montelukast (a synthetic anti-inflammatory drug) and Bixin (an apo-carotenoid) as SCD1 inhibitors for treating fatty liver disease. Bixin was identified through virtual screening of a curated carotenoid database (carotenoid DB) targeting lipogenic enzyme SCD1. In the in vitro model of steatotic HepG2 cells, the combination treatment of Mon

SUBMITTER: Puri S 

PROVIDER: S-EPMC12529210 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature